RxDoctor Payments Data

Harmeet Gurm, MD

Nephrology · Fresno, CANPI 1972831790

Payments from drug & device makers

$46,439in general payments, 2019–2025

Across 217 payments — averaging $214.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Vifor Pharma, Inc.$14K
  • Bayer$12K
  • Amgen$756
  • Otsuka America Pharmaceutical, Inc.$244
  • Travere Therapeutics, Inc.$239
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$3,6008%
  • Speaking & faculty fees$36,17478%
  • Travel & lodging$1,9674%
  • Food & beverage$4,68510%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,439 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$497,012
Medicare patients
813
Services billed
14,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate93$126,057
VelphoroSucroferric Oxyhydroxide30$116,934
KerendiaFinerenone36$57,198
XphozahTenapanor Hcl19$51,883
VeltassaPatiromer Calcium Sorbitex31$45,255
ClinolipidFat Emulsion/Olive/Soy/Phospho75$23,961
ProsolParenteral Amino Acid 20% No.1102$20,910
JardianceEmpagliflozin15$19,971
FarxigaDapagliflozin Propanediol16$14,591
Sevelamer Carbonate53$12,365
Hydralazine Hcl484$8,465
Cinacalcet Hcl21$6,311
Sevelamer Hcl11$5,411
Calcitriol320$5,108
Bumetanide84$3,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$18,266$140,648109 claims
Fresenius USA Marketing, Inc.Velphoro$40$116,93430 claims
BayerKerendia$11,793$57,19836 claims
Boehringer IngelheimJardiance$42$19,97115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →